CRA provided an expert opinion on liability in an ICDR proceeding between parties to a license agreement concerning development and commercialization of a pharmaceutical product in Japan. On behalf of the respondent, CRA addressed whether it was commercially reasonable to cease development of the product given the information available at the time. CRA developed projections of the market opportunity and modeled the expected net present value associated with continued development activity. Under reasonable scenarios of product launch and market assessment, it was found that the present value of development costs exceeded the present value of expected operating profits.
2023 International Arbitration review: Updates and trends
2023 marked a significant surge in activity across diverse sectors such as mining, oil & gas, the energy transition, pharma, and merger disputes. Throughout...